1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted

2. Executive Summary
2.1. Market Snapshot: Global Pre-Menstrual Syndrome Treatment Market
2.3. Global Pre-Menstrual Syndrome Treatment Market, By Drugs Type, 2025 (US$ Million)
2.4. Global Pre-Menstrual Syndrome Treatment Market, By Geography, 2025 (US$ Million)
2.5. Attractive Investment Proposition by Geography, 2025

3. Pre-Menstrual Syndrome Treatment Market: Competitive Analysis
3.1. Market Positioning of Key Pre-Menstrual Syndrome Treatment Market Vendors
3.2. Strategies Adopted by Pre-Menstrual Syndrome Treatment Market Vendors

4. Pre-Menstrual Syndrome Treatment Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Pre-Menstrual Syndrome Treatment Market Value, 2024 - 2034, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. Porter's Five Force Model
4.5.1. Supplier Power
4.5.2. Buyer Power
4.5.3. Threat Of Substitutes
4.5.4. Threat Of New Entrants
4.5.5. Competitive Rivalry
4.6. PESTEL Analysis
4.6.1. Political Landscape
4.6.2. Economic Landscape
4.6.3. Social Landscape
4.6.4. Technology Landscape
4.6.5. Environmental Landscape
4.6.6. Legal Landscape

5. Pre-Menstrual Syndrome Treatment Market: By Drugs Type, 2024-2034, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2025 Versus 2034
5.3. Market Segmentation
5.3.1. Analgesics (pain killers)
5.3.2. Oral Contraceptive Pills (OCPs)
5.3.3. Gonadotropin-releasing Hormone (GnRH)
5.3.4. Antidepressants
5.3.5. Ovarian Suppressors
5.3.6. Diuretics
5.3.7. Benzodiazepines

6. North America Pre-Menstrual Syndrome Treatment Market, 2024-2034, USD (Million)
6.1. Market Overview
6.2. Pre-Menstrual Syndrome Treatment Market: By Drugs Type, 2024-2034, USD (Million)
6.3. Pre-Menstrual Syndrome Treatment Market: By Region, 2024-2034, USD (Million)
6.3.1.North America
6.3.1.1. U.S.
6.3.1.1.1. Pre-Menstrual Syndrome Treatment Market: By Drugs Type, 2024-2034, USD (Million)
6.3.1.2. Canada
6.3.1.2.1. Pre-Menstrual Syndrome Treatment Market: By Drugs Type, 2024-2034, USD (Million)
6.3.1.3. Rest of North America
6.3.1.3.1. Pre-Menstrual Syndrome Treatment Market: By Drugs Type, 2024-2034, USD (Million)

7. UK and European Union Pre-Menstrual Syndrome Treatment Market, 2024-2034, USD (Million)
7.1. Market Overview
7.2. Pre-Menstrual Syndrome Treatment Market: By Drugs Type, 2024-2034, USD (Million)
7.3. Pre-Menstrual Syndrome Treatment Market: By Region, 2024-2034, USD (Million)
7.3.1.UK and European Union
7.3.1.1. UK
7.3.1.1.1. Pre-Menstrual Syndrome Treatment Market: By Drugs Type, 2024-2034, USD (Million)
7.3.1.2. Germany
7.3.1.2.1. Pre-Menstrual Syndrome Treatment Market: By Drugs Type, 2024-2034, USD (Million)
7.3.1.3. Spain
7.3.1.3.1. Pre-Menstrual Syndrome Treatment Market: By Drugs Type, 2024-2034, USD (Million)
7.3.1.4. Italy
7.3.1.4.1. Pre-Menstrual Syndrome Treatment Market: By Drugs Type, 2024-2034, USD (Million)
7.3.1.5. France
7.3.1.5.1. Pre-Menstrual Syndrome Treatment Market: By Drugs Type, 2024-2034, USD (Million)
7.3.1.6. Rest of Europe
7.3.1.6.1. Pre-Menstrual Syndrome Treatment Market: By Drugs Type, 2024-2034, USD (Million)

8. Asia Pacific Pre-Menstrual Syndrome Treatment Market, 2024-2034, USD (Million)
8.1. Market Overview
8.2. Pre-Menstrual Syndrome Treatment Market: By Drugs Type, 2024-2034, USD (Million)
8.3. Pre-Menstrual Syndrome Treatment Market: By Region, 2024-2034, USD (Million)
8.3.1.Asia Pacific
8.3.1.1. China
8.3.1.1.1. Pre-Menstrual Syndrome Treatment Market: By Drugs Type, 2024-2034, USD (Million)
8.3.1.2. Japan
8.3.1.2.1. Pre-Menstrual Syndrome Treatment Market: By Drugs Type, 2024-2034, USD (Million)
8.3.1.3. India
8.3.1.3.1. Pre-Menstrual Syndrome Treatment Market: By Drugs Type, 2024-2034, USD (Million)
8.3.1.4. Australia
8.3.1.4.1. Pre-Menstrual Syndrome Treatment Market: By Drugs Type, 2024-2034, USD (Million)
8.3.1.5. South Korea
8.3.1.5.1. Pre-Menstrual Syndrome Treatment Market: By Drugs Type, 2024-2034, USD (Million)
8.3.1.6. Rest of Asia Pacific
8.3.1.6.1. Pre-Menstrual Syndrome Treatment Market: By Drugs Type, 2024-2034, USD (Million)

9. Latin America Pre-Menstrual Syndrome Treatment Market, 2024-2034, USD (Million)
9.1. Market Overview
9.2. Pre-Menstrual Syndrome Treatment Market: By Drugs Type, 2024-2034, USD (Million)
9.3. Pre-Menstrual Syndrome Treatment Market: By Region, 2024-2034, USD (Million)
9.3.1.Latin America
9.3.1.1. Brazil
9.3.1.1.1. Pre-Menstrual Syndrome Treatment Market: By Drugs Type, 2024-2034, USD (Million)
9.3.1.2. Mexico
9.3.1.2.1. Pre-Menstrual Syndrome Treatment Market: By Drugs Type, 2024-2034, USD (Million)
9.3.1.3. Rest of Latin America
9.3.1.3.1. Pre-Menstrual Syndrome Treatment Market: By Drugs Type, 2024-2034, USD (Million)

10. Middle East and Africa Pre-Menstrual Syndrome Treatment Market, 2024-2034, USD (Million)
10.1. Market Overview
10.2. Pre-Menstrual Syndrome Treatment Market: By Drugs Type, 2024-2034, USD (Million)
10.3. Pre-Menstrual Syndrome Treatment Market: By Region, 2024-2034, USD (Million)
10.3.1.Middle East and Africa
10.3.1.1. GCC
10.3.1.1.1. Pre-Menstrual Syndrome Treatment Market: By Drugs Type, 2024-2034, USD (Million)
10.3.1.2. Africa
10.3.1.2.1. Pre-Menstrual Syndrome Treatment Market: By Drugs Type, 2024-2034, USD (Million)
10.3.1.3. Rest of Middle East and Africa
10.3.1.3.1. Pre-Menstrual Syndrome Treatment Market: By Drugs Type, 2024-2034, USD (Million)

11. Company Profile
11.1. Alva-Amco Pharmacal Cos., Inc. (Company Overview, Financial Performance, Product Portfolio, Strategic Initiatives)
11.2. Bayer, Inc.
11.3. Chattem, Inc. (Sanofi)
11.4. DEKK-TEC, Inc.
11.5. G. R. Lane Health Products Ltd
11.6. McNeil Consumer Healthcare
11.7. MetP Pharma AG
11.8. Pherin Pharmaceuticals, Inc.
11.9. Umecrine Mood AB
11.10. Umecrine Mood AB
11.11. Novartis AG
11.12. GlaxoSmithKline Plc